Compare ACADIA Pharmaceuticals Inc. (ACAD) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs New York Times Co — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.54 (market cap $5.07B), while New York Times Co trades at $63.73 (market cap $10.28B). The key difference: New York Times Co is far larger — about 2× ACADIA Pharmaceuticals Inc.'s market cap, and New York Times Co pays a 1.44% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | NYT | |
|---|---|---|
Market Cap | $5.07B | $10.28B |
Sector | Health | Media |
52-Week High | $29.41 | $85.86 |
52-Week Low | $20.06 | $54.66 |
Enterprise Value | $4.19B | $9.67B |
Dividend Yield | — | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
The New York Times (NYT) stock trades at $64.21, down 0.91% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth remains steady, reaching $2.82 billion in 2025, with net income margins improving to 12.17%. The company faces headwinds from slowing digital subscriber growth, as highlighted in recent quarterly reports, but maintains strong profitability and cash flow generation.
Outlook is mixed; valuation appears full with a P/E of 26.55, yet analyst consensus targets $77.50 suggest upside. Key risks include subscriber growth moderation and competitive pressures. The stock offers a dividend yield with the next payment scheduled for July 23, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
